Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Common Equity (2016 - 2025)

Historic Common Equity for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $133.2 million.

  • Zevra Therapeutics' Common Equity rose 9086.28% to $133.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $133.2 million, marking a year-over-year increase of 9086.28%. This contributed to the annual value of $39.7 million for FY2024, which is 3588.19% down from last year.
  • According to the latest figures from Q3 2025, Zevra Therapeutics' Common Equity is $133.2 million, which was up 9086.28% from $117.2 million recorded in Q2 2025.
  • Zevra Therapeutics' Common Equity's 5-year high stood at $439.6 million during Q2 2023, with a 5-year trough of $32.5 million in Q2 2024.
  • Over the past 5 years, Zevra Therapeutics' median Common Equity value was $117.2 million (recorded in 2025), while the average stood at $175.4 million.
  • As far as peak fluctuations go, Zevra Therapeutics' Common Equity skyrocketed by 41322.24% in 2022, and later tumbled by 9261.19% in 2024.
  • Zevra Therapeutics' Common Equity (Quarter) stood at $127.1 million in 2021, then tumbled by 40.91% to $75.1 million in 2022, then fell by 17.65% to $61.9 million in 2023, then crashed by 35.88% to $39.7 million in 2024, then skyrocketed by 235.72% to $133.2 million in 2025.
  • Its Common Equity was $133.2 million in Q3 2025, compared to $117.2 million in Q2 2025 and $41.0 million in Q1 2025.